US FDA Orders New Warnings for GlaxoSmithKline, AstraZeneca PLC Drugs

June 3, 2010 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

Reuters -- U.S. health regulators have finalized new warnings for controversial inhaled asthma drugs, but exercised new powers to order the changes on products made by GlaxoSmithKline Plc and AstraZeneca Plc.

Twitter
LinkedIn
Facebook
Email
Print

Clinical research Postmarket research

AstraZeneca Pharmaceuticals LP GlaxoSmithKline Food and Drug Administration (FDA)